Forget the Pro Forma: Opening a New Senior Housing Community During COVID-19

New senior housing communities that opened just prior to the industry disruption wrought by the coronavirus pandemic are contending with partially empty buildings, residents in lockdown, increased spending on supplies and elongated lease timetables.

To read an excerpt of this article quoting Duane Morris partner John Robert Weiss, please visit the firm website. To read the full text, please visit the Senior Housing News website.

Reopening the Economy, Business Resiliency and Change

(This is the fifth in a series on the impacts of the coronavirus on employment and the workplace. Read part onepart twopart three and part four.)

On Friday, President Trump announced a task force on reopening the national economy. Also on Friday, several Governors, including California Governor Newsom, announced they were developing plans on state reopening processes and strategies. Continue reading “Reopening the Economy, Business Resiliency and Change”

New Jersey extends GROW NJ, ERG and HUB Filing Deadlines Due to COVID-19

The New Jersey Economic Development Authority (NJEDA) has extended the annual reporting deadlines for businesses that received tax credits through the Grow New Jersey, Economic Redevelopment & Growth (ERG) and Urban Transit Hub (HUB) programs because of the impact of COVID-19, the EDA announced on April 13, 2020.

To read the full text of this post by Duane Morris partner Brad Molotsky, please visit the Duane Morris Project Development/Infrastructure/P3 Blog.

HHS Announces Initial $30 Billion Distribution from CARES Act Provider Relief Fund

Immediate funds are now available for providers to receive a cash influx at a critical time. The challenge will not be receiving the funds, but rather keeping the funds after a future audit of compliance with the terms and conditions.

On April 10, 2020, the United States Department of Health and Human Services (HHS) announced the immediate distribution of an initial $30 billion in relief funding to providers in support of the nationwide COVID-19 response. The distribution is part of the $100 billion provider relief fund included in the Coronavirus Aid, Relief and Economic Security (CARES) Act recently passed by Congress. Importantly, HHS has noted that these are payments, not loans, to healthcare providers, and will not need to be repaid unless the provider does not comply with the terms and conditions.

To read the full text of this Duane Morris Alert, please visit the firm website.

CARES Act Expands Immunity Protections for Covered Countermeasures and Healthcare Volunteers

As discussed in our March 18 Alert, the Secretary of Health and Human Services has issued a declaration authorizing drugs, devices and biologics used to treat or mitigate COVID-19 as covered countermeasures under the Public Readiness and Emergency Preparedness (PREP) Act. Following Secretary Azar’s declaration of a public health emergency, covered persons may obtain immunity under federal law for all claims arising from manufacturing, distributing or administering covered countermeasures, subject to the conditions laid out at 42 U.S.C. § 247d-6d, the declaration and other applicable regulations.

Subsequent to our previous Alert, President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act (CARES Act), which expanded the covered countermeasure protections offered by the PREP Act.

To read the full text of this Duane Morris Alert, please visit the firm website.

FDC Changes OTC Drug Review Process in Response to CARES Act

Most of the hundreds of pages comprising the CARES Act, signed into law on March 27, 2020, concern measures for directly counteracting COVID-19 and assisting those dealing with economic consequences of the pandemic. Yet tucked away in Subtitle F of the legislation are a number of provisions—now law—which streamline FDA’s over-the-counter (OTC) drug review process. These changes are likely to lower the regulatory burden of getting a product through the OTC drug review process and provide incentives of market exclusivity for companies who do.

To read the full text of this Duane Morris Alert, please visit the firm website.

Webinar: How COVID-19 Is Affecting Life Sciences and Medical Technologies

Duane Morris will be hosting the webinar, “How COVID-19 Is Affecting Life Sciences and Medical Technologies,” on April 16, 2020, from 1:00 p.m. to 2:00 p.m. (Eastern).

Join Duane Morris attorneys for a discussion on how the life sciences and medical technologies industry is responding and adapting to the COVID-19 pandemic, including:

  • FDA’s Emergency Use Authorizations (EUAs) for devices and diagnostics testing policies
  • Public Readiness and Emergency Preparedness Act (PREP Act) immunity from liability
  • Implications on intellectual property, such as patent strategy, in biotechnology and pharmaceuticals
  • License and collaboration agreements in the wake of COVID-19

For more information and to register, please visit the firm website.

Singapore: Legislative Framework for Security and Use of Electronic Signatures

For most of us working from home and actively telecommuting to help stem the tide of local transmissions of COVID-19 during this crucial period of time, technological advancements in the medium of digital communication and remote access have been a boon.

It is thus timely to restate the guiding principles of “electronic signatures” and its use in electronic records and transactions that have become increasingly commonplace.

To read the full text of this article, please visit the Duane Morris & Selvam COVID-19 Resource Blog.

Update: Dealing with COVID-19 in the Construction Industry in Singapore

This update is provided to our article issued on 5 April 2020.

On Friday 3 April 2020, to reduce the risk of further local transmission of COVID-19, the Building and Construction Authority (BCA) released an advisory to inform contractors that all building works (except for essential works) are to cease from 7 April 2020 to 4 May 2020 (“Stop Work Period”).

To read the full text of this article, please visit the Duane Morris & Selvam COVID-19 Resource Blog.

© 2009- Duane Morris LLP. Duane Morris is a registered service mark of Duane Morris LLP.

The opinions expressed on this blog are those of the author and are not to be construed as legal advice.

Proudly powered by WordPress